Wang Si, Zhang Lin, Wu Yigao, Ma Jun
Department of Psychiatry, Wuhan Mental Health Center, Wuhan, People's Republic of China.
Department of Psychiatry, Wuhan Hospital for Psychotherapy, Wuhan, People's Republic of China.
Neuropsychiatr Dis Treat. 2024 Nov 14;20:2159-2168. doi: 10.2147/NDT.S494619. eCollection 2024.
Major depressive disorder (MDD) and metabolic syndrome (MetS) are both major health threats nowadays, and the relationship between them is complex and close. The purpose of this paper is to compare differences in the prevalence and risk factors of MetS in first hospitalized patients with MDD with and without antidepressant exposure.
A total of 636 first hospitalized MDD patients (study group) with antidepressant exposure and 345 drug-naïve patients (control group) were included in this study. Their socio-demographic data, routine biochemical indices, and psychological symptom assessment were collected.
There was no difference in the prevalence of MetS between the study group and the control group (F = 2.49, p = 0.115). Factors affecting MetS and its severity differed between the two groups, in the study group, the identified risk factors for MetS were onset age (B = 0.05, p <0.001, OR = 1.05, 95% CI = 1.02-1.08), TSH level (B = 0.42, p <0.001, OR = 1.53, 95% CI = 1.39-1.68). Meanwhile, in the control group, the identified risk factors for MetS were more extensive and they were, onset age (B = 0.11, p <0.001, OR = 1.12, 95% CI = 1.07-1.16), suicidal behavior (B = 1.54, p = 0.007, OR = 4.65, 95% CI = 1.51-14.33), HAMD scores (B = 0.23, p = 0.008, OR = 1.26, 95% CI = 1.06-1.49) and TSH levels (B = 0.33, p <0.001, OR = 1.39, 95% CI = 1.17-1.65). The number of risk factors identified was lower in the study group.
Antidepressant use was associated with greater MetS severity but did not affect overall prevalence. Antidepressants appear to modify MetS risk factors, highlighting the need to differentiate these effects from those in drug-naïve patients when developing MetS interventions for the MDD population.
重度抑郁症(MDD)和代谢综合征(MetS)都是当今主要的健康威胁,它们之间的关系复杂且密切。本文旨在比较首次住院的伴有和不伴有抗抑郁药暴露的MDD患者中MetS的患病率及危险因素的差异。
本研究纳入了636例首次住院且有抗抑郁药暴露的MDD患者(研究组)和345例未使用过药物的患者(对照组)。收集了他们的社会人口学数据、常规生化指标及心理症状评估结果。
研究组和对照组之间MetS的患病率无差异(F = 2.49,p = 0.115)。两组中影响MetS及其严重程度的因素有所不同,在研究组中,确定的MetS危险因素为发病年龄(B = 0.05,p <0.001,OR = 1.05,95%CI = 1.02 - 1.08)、促甲状腺激素(TSH)水平(B = 0.42,p <0.001,OR = 1.53,95%CI = 1.39 - 1.68)。同时,在对照组中,确定的MetS危险因素更广泛,包括发病年龄(B = 0.11,p <0.001,OR = 1.12,95%CI = 1.07 - 1.16)、自杀行为(B = 1.54,p = 0.007,OR = 4.65,95%CI = 1.51 - 14.33)、汉密尔顿抑郁量表(HAMD)评分(B = 0.23,p = 0.008,OR = 1.26,95%CI = 1.06 - 1.49)和TSH水平(B = 0.33,p <0.001,OR = 1.39,95%CI = 1.17 - 1.65)。研究组中确定的危险因素数量较少。
使用抗抑郁药与MetS更严重的程度相关,但不影响总体患病率。抗抑郁药似乎改变了MetS的危险因素,这突出了在为MDD人群制定MetS干预措施时,需要将这些影响与未使用药物患者的影响区分开来。